🎉 M&A multiples are live!
Check it out!

Genomictree Valuation Multiples

Discover revenue and EBITDA valuation multiples for Genomictree and similar public comparables like Biohit, Proteomics International, and Avacta Group.

Genomictree Overview

About Genomictree

Genomictree Inc is a molecular diagnostic company. It is engaged in developing technologies that satisfies the unmet needs of the healthcare market.


Founded

2000

HQ

South Korea
Employees

n/a

Website

genomictree.com

Financials

LTM Revenue $17.8M

LTM EBITDA -$8.1M

EV

$183M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Genomictree Financials

Genomictree has a last 12-month revenue of $17.8M and a last 12-month EBITDA of -$8.1M.

In the most recent fiscal year, Genomictree achieved revenue of $1.6M and an EBITDA of -$6.1M.

Genomictree expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Genomictree valuation multiples based on analyst estimates

Genomictree P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $2.3M $1.6M XXX XXX XXX
Gross Profit $17.0M -$0.2M XXX XXX XXX
Gross Margin 731% -11% XXX XXX XXX
EBITDA -$4.3M -$6.1M XXX XXX XXX
EBITDA Margin -183% -377% XXX XXX XXX
Net Profit -$4.5M -$6.0M XXX XXX XXX
Net Margin -194% -371% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Genomictree Stock Performance

As of April 15, 2025, Genomictree's stock price is KRW 15110 (or $10).

Genomictree has current market cap of KRW 362B (or $247M), and EV of KRW 268B (or $183M).

See Genomictree trading valuation data

Genomictree Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$183M $247M XXX XXX XXX XXX $-0.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Genomictree Valuation Multiples

As of April 15, 2025, Genomictree has market cap of $247M and EV of $183M.

Genomictree's trades at 10.3x LTM EV/Revenue multiple, and -22.5x LTM EBITDA.

Analysts estimate Genomictree's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Genomictree and 10K+ public comps

Genomictree Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $183M XXX XXX XXX
EV/Revenue 113.7x XXX XXX XXX
EV/EBITDA -30.2x XXX XXX XXX
P/E -35.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -16.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Genomictree Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Genomictree Valuation Multiples

Genomictree's NTM/LTM revenue growth is 1%

Genomictree's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Genomictree's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Genomictree's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Genomictree and other 10K+ public comps

Genomictree Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -31% XXX XXX XXX XXX
EBITDA Margin -377% XXX XXX XXX XXX
EBITDA Growth 42% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -375% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 88% XXX XXX XXX XXX
G&A Expenses to Revenue 18% XXX XXX XXX XXX
R&D Expenses to Revenue 209% XXX XXX XXX XXX
Opex to Revenue 617% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Genomictree Public Comps

See public comps and valuation multiples for Pharma Diagnostics & Analytics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Zomedica XXX XXX XXX XXX XXX XXX
AnteoTech XXX XXX XXX XXX XXX XXX
Proteomics International XXX XXX XXX XXX XXX XXX
Biohit XXX XXX XXX XXX XXX XXX
Avacta Group XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Genomictree M&A and Investment Activity

Genomictree acquired  XXX companies to date.

Last acquisition by Genomictree was  XXXXXXXX, XXXXX XXXXX XXXXXX . Genomictree acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Genomictree

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Genomictree

When was Genomictree founded? Genomictree was founded in 2000.
Where is Genomictree headquartered? Genomictree is headquartered in South Korea.
Is Genomictree publicy listed? Yes, Genomictree is a public company listed on KRX.
What is the stock symbol of Genomictree? Genomictree trades under 228760 ticker.
When did Genomictree go public? Genomictree went public in 2016.
Who are competitors of Genomictree? Similar companies to Genomictree include e.g. Zomedica, AnteoTech, Proteomics International, Biohit.
What is the current market cap of Genomictree? Genomictree's current market cap is $247M
What is the current revenue of Genomictree? Genomictree's last 12-month revenue is $17.8M.
What is the current EBITDA of Genomictree? Genomictree's last 12-month EBITDA is -$8.1M.
What is the current EV/Revenue multiple of Genomictree? Current revenue multiple of Genomictree is 10.3x.
What is the current EV/EBITDA multiple of Genomictree? Current EBITDA multiple of Genomictree is -22.5x.
What is the current revenue growth of Genomictree? Genomictree revenue growth between 2023 and 2024 was -31%.
Is Genomictree profitable? Yes, Genomictree is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.